Antiphospholipid syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
Feham Tariq (talk | contribs) |
Feham Tariq (talk | contribs) |
||
Line 8: | Line 8: | ||
* Anticoagulation in patients with risk factors for arterial and venous thrombosis. | * Anticoagulation in patients with risk factors for arterial and venous thrombosis. | ||
* Minimizing the contribution of reversible risk factors for recurrent thrombosis. | * Minimizing the contribution of reversible risk factors for recurrent thrombosis. | ||
* A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies. | |||
==References== | ==References== |
Revision as of 18:41, 11 April 2018
Antiphospholipid syndrome Microchapters |
Differentiating Antiphospholipid syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Antiphospholipid syndrome primary prevention On the Web |
American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention |
Risk calculators and risk factors for Antiphospholipid syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Primary Prevention
The primary prevention of antiphospholipid syndrome is as follows:
- Anticoagulation in patients with risk factors for arterial and venous thrombosis.
- Minimizing the contribution of reversible risk factors for recurrent thrombosis.
- A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.